Kontafarma China Tightens Audit Committee Mandate to Bolster Governance and Oversight

Kontafarma China Holdings Ltd ( (HK:1312) ) has shared an update.

Kontafarma China Holdings Ltd has formalised updated terms of reference for its Audit Committee, stipulating that it must comprise at least three non-executive directors, with a majority being independent non-executive directors and at least one member possessing appropriate professional or accounting and financial management expertise as required under Hong Kong Listing Rules. The document strengthens the committee’s authority and procedures by setting minimum meeting frequency, quorum requirements, the ability to hold private sessions with internal and external auditors, and explicit powers to seek information from management, report suspected frauds, control failures or regulatory breaches to the board, and obtain independent professional advice at the company’s expense, underscoring a tighter governance and risk oversight framework for stakeholders.

The most recent analyst rating on (HK:1312) stock is a Hold with a HK$0.03 price target. To see the full list of analyst forecasts on Kontafarma China Holdings Ltd stock, see the HK:1312 Stock Forecast page.

More about Kontafarma China Holdings Ltd

Kontafarma China Holdings Ltd is a Cayman Islands–incorporated company listed on The Stock Exchange of Hong Kong, operating as a corporate group with a board comprising executive and non-executive directors and subject to Hong Kong Listing Rules and corporate governance requirements.

Average Trading Volume: 1,707,185

Technical Sentiment Signal: Sell

Current Market Cap: HK$156.2M

Learn more about 1312 stock on TipRanks’ Stock Analysis page.